Singlomics Announces First Patient Dosed in Phase I Clinical Trial of DXP-106 (IL-1RAP mAb) in China
BEIJING, April 7, 2026 /PRNewswire/ -- Singlomics Biopharmaceuticals, an innovative clinical-stage biopharmaceutical company focused on the discovery and development of antibody therapeutics for oncology, inflammation, and autoimmune diseases, today...
ArkBio Announces the Completion of Phase III Clinical Study for AK0901 in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in China
SHANGHAI, March 24, 2025 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced the successful completion of the Phase III clinical study of AK0901, a novel drug for the treatment of attention deficit hyperactivity...
L&C Bio Secures World's First NMPA Approval for 'MegaDerm Plus' in China
SEONGNAM-SI, South Korea, Jan. 22, 2025 /PRNewswire/ -- L&C Bio (CEO Hwan-Chul Lee) has achieved a significant milestone in its global market strategy by becoming the first company worldwide to secure approval from China's National Medical...
Cistto Launches the "Humanized Anti-Aging Global Scientist Alliance" in China, Empowering Products with Cutting-Edge Science
LOS ANGELES, Nov. 25, 2024 /PRNewswire/ -- As an emerging brand specializing in sensitive skin repair, Cistto is grounded in skin science and committed to advancing skin health through the latest dermatological breakthroughs and cutting-edge...
